EXPERIENCE WITH ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH NEUROLOGICAL MANIFESTATIONS
Bibliographic record
Abstract
PV300 / #635 Case Report Poster Topic: AS24 - SLE-Treatment Introduction Anifrolumab, a biologic approved for systemic lupus erythematosus (SLE), excludes patients with active neurological manifestations in clinical trials. However, real-world clinical practice often necessitates its use in this population when other options are limited. This study analyzes the effectiveness of Anifrolumab in 3 SLE patients with neurological involvement. Case Presentation With Investigation We retrospectively reviewed 3 female patients treated with Anifrolumab who presented with neurological manifestations in addition to systemic disease. Clinical characteristics, treatment response, and safety outcomes were evaluated. Literature Review • Case 1: A 29-year-old woman with cutaneous and hematological SLE presented with acute psychosis. Extensive workup, including neuroimaging, lumbar puncture, and infection studies, was negative. She was treated with corticosteroid pulses followed by Anifrolumab, achieving disease remission and discontinuing corticosteroids after 6 months. • Case 2: A patient with moderate-to-severe hematological SLE refractory to mycophenolate also presented with neurological involvement. Anifrolumab was initiated but discontinued after 3 months due to refractory thrombocytopenia and a cerebrovascular event. • Case 3: A woman with articular, hematological, and cutaneous SLE, including significant alopecia and recurrent lupus headaches requiring steroid pulses, achieved disease remission with Anifrolumab. Additionally, no steroid pulses were required for 6 months after treatment initiation. Discussion Anifrolumab demonstrated effectiveness in some SLE patients with neurological manifestations, particularly in reducing corticosteroid use and managing lupus headache. However, safety concerns, such as thrombocytopenia and cerebrovascular events, warrant careful monitoring. These cases highlight the need for further studies to assess Anifrolumab’s role in patients with neurological involvement.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".